BioIVT acquires donor center to bring fresh blood products to European clients

By Maggie Lynch

- Last updated on GMT

(Image: Getty/Takasuu)
(Image: Getty/Takasuu)

Related tags Blood Preclinical services Cell

BioIVT has acquired Clinical Trials Laboratory Services, a UK-based donor center, in an aim to provide fresh blood products to clients.

Clinical Trials Laboratory Services (CTLS) provides serum, plasma, and blood collection services, with full-service cell processing capabilities on site.

With the acquisition, BioIVT will offer fresh blood and blood-derived products as well as expand its immune cell offering to clients.

Courtney Noah, BioIVT VP told us, “We were interested in expanding our footprint in Europe by offering fresh blood and blood-derived products. We already do this for our US clients and know that it is something that our European clients have a strong need for.”

Noah explained that in recent years BioIVT has worked to build a portfolio of normal and disease-state human specimens, including tissues, biofluids, and cellular products. With the acquisition of CTLS this portfolio can grow to make BioIVT a supplier of biospecimens to the global research community, he said.

All CTLS employees will join BioIVT after the acquisition and the current CTLS London headquarters will become the primary site for donor collections. The company stated that it will aim to enhance the acquired laboratory’s capabilities with a specific focus on increasing immune cell isolation abilities.

BioIVT says that per this acquisition it will have a space to provide a ‘consistent’ supply of fresh blood and blood products for research. Noah said the company will be looking to expand its collection capabilities at the CTLS site to “stay ahead of client demand.”

“We also see this as an opportunity to expand our clinical collections for disease-state donors, an area of growth for us in Europe. Another early focus of the integration will be on enhancing the laboratory capabilities for us in Europe.”

Noah said CTLS employees will be trained on additional protocols and control procedures to focus on the delivery of fresh blood-derived products across the region. 

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us